Assyro AI

Orange Book product · Brand (NDA)

CINVANTI

APREPITANT

Brand (NDA)NDA 209296RX HERON THERAPS INC

At a glance

Nov 09, 2017

Approved

Brand (NDA)

Application

Not listed

TE code

13

Listed patents

Key dates

  1. Approval

    FDA approval date of this drug product.

    Nov 09, 2017

    8 yr 9 mo ago

  2. Today

  3. Patent 10500208 expires

    Listed drug product patent expiration.

    Sep 18, 2035

    in 9 yr 5 mo

  4. Patent 10624850 expires

    Listed method-of-use patent (U-2161) expiration.

    Sep 18, 2035

    in 9 yr 5 mo

  5. Patent 10953018 expires

    Listed method-of-use patent (U-2161) expiration.

    Sep 18, 2035

    in 9 yr 5 mo

  6. Patent 11173118 expires

    Listed drug product patent expiration.

    Sep 18, 2035

    in 9 yr 5 mo

  7. Patent 11744800 expires

    Listed drug product patent expiration.

    Sep 18, 2035

    in 9 yr 5 mo

  8. Patent 12115254 expires

    Listed drug product patent expiration.

    Sep 18, 2035

    in 9 yr 5 mo

  9. Patent 12115255 expires

    Listed drug product patent expiration.

    Sep 18, 2035

    in 9 yr 5 mo

  10. Patent 12290520 expires

    Listed drug product patent expiration.

    Sep 18, 2035

    in 9 yr 5 mo

  11. Patent 9561229 expires

    Listed drug product patent expiration.

    Sep 18, 2035

    in 9 yr 5 mo

  12. Patent 9808465 expires

    Listed method-of-use patent (U-2161) expiration.

    Sep 18, 2035

    in 9 yr 5 mo

  13. Patent 9974742 expires

    Listed drug product patent expiration.

    Sep 18, 2035

    in 9 yr 5 mo

  14. Patent 9974793 expires

    Listed drug product patent expiration.

    Sep 18, 2035

    in 9 yr 5 mo

  15. Patent 9974794 expires

    Listed drug product patent expiration.

    Sep 18, 2035

    in 9 yr 5 mo

Pharmaceutical detail

Active ingredient

APREPITANT

Strength

130MG/18ML (7.2MG/ML)

Dosage form

EMULSION

Route

INTRAVENOUS

TE code

Not listed

Application

NDA 209296

Product number

001

Marketing status

RX

Reference listed drug (RLD)

Yes

Reference standard (RS)

Yes

Active-ingredient family

View full family

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Listed patents (13)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
10500208Sep 18, 2035in 9 yr 5 mo
Product
10624850Sep 18, 2035in 9 yr 5 mo
U-2161
10953018Sep 18, 2035in 9 yr 5 mo
U-2161
11173118Sep 18, 2035in 9 yr 5 mo
Product
11744800Sep 18, 2035in 9 yr 5 mo
Product
12115254Sep 18, 2035in 9 yr 5 mo
Product
12115255Sep 18, 2035in 9 yr 5 mo
Product
12290520Sep 18, 2035in 9 yr 5 mo
Product
9561229Sep 18, 2035in 9 yr 5 mo
ProductU-2161
9808465Sep 18, 2035in 9 yr 5 mo
U-2161
9974742Sep 18, 2035in 9 yr 5 mo
Product
9974793Sep 18, 2035in 9 yr 5 mo
Product
9974794Sep 18, 2035in 9 yr 5 mo
ProductU-2161
Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.